Speedel Pharmaceuticals, Inc. Release: New Data On Renin Inhibitor SPP100 (Rasilez) Demonstrates Its Potential Use In Diabetic Patients
Speedel (SWX: SPPN) is very pleased with the Phase III clinical data on SPP100 (Rasilez 1) in the treatment of hypertension in diabetic patients presented today by Novartis in Madrid at the 16th Meeting of the European Society of Hypertension (ESH). The data demonstrated the robust efficacy and good safety profile of SPP100 as a monotherapy and in co-administration with ramipril, an ACE2 inhibitor. SPP100 is the first-in-class once daily oral renin inhibitor that Speedel successfully developed through Phase I and II clinical trials before Novartis exercised its license-back option in 2002. The U.S. Food and Drug Administration (FDA) in April 2006 accepted for review Novartis’ new drug application (NDA) for SPP100 as a treatment for hypertension both as monotherapy and in co-administration with other anti-hypertensives.